Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate cancer that has spread to other regions of the body is commonly treated with hormone treatment, but many individuals develop resistance to it, making their disease more aggressive and potentially fatal.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
Researchers are rushing to review a group of bacteria known as actinomycetes, which are one of the most successful sources of treatment.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Cedars-Sinai scientists discovered that attacking a protein present in prostate cancer cells could stop the disease from further spreading to various other parts of the body.
The detection and quantification of cancer-associated molecular biomarkers in body fluids, or liquid biopsies, prove minimally invasive in early cancer diagnostics.
A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A.
Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.
Prostate cancer is the most commonly diagnosed cancer in men and is among the top five causes of cancer-related death. In most cases, prostate cancer can be successfully treated but there is a group of patients who suffer an aggressive course and often fatal outcome.
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the study were published in Cancer Epidemiology, Biomarkers & Prevention.
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
Researchers at Université de Montréal and McGill University have discovered a new multi-enzyme complex that reprograms metabolism and overcomes “cellular senescence,” when aging cells stop dividing.
In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.
Scientists headed by the University of Michigan Rogel Cancer Center converted an immune cold cancer into one that responds to immunotherapy.
A new study reports the use of single-cell, force spectroscopy methods to probe biophysical and biomechanical kinetics of cancer cells.
Oncotarget published "Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy" which reported that by exploiting single-cell, force spectroscopy methods, the authors probed biophysical and biomechanical kinetics of brain, breast, prostate, and pancreatic cancer cells with standard chemotherapeutic drugs in normoxia and hypoxia over 12-24 hours.
In our latest interview, AZoLifeSciences spoke to a team of researchers about their latest research which involved carrying out CRISPR/Cas9 in Space.
A new study analyzing the association between an individual's genetics (genotype) and their observable characteristics resulting from the interaction of genetics and the environment (phenotype), contributes new knowledge to the understanding of human complex traits and diseases.
Malignant tumor cells undergo mechanical deformation more easily than normal cells, allowing them to migrate throughout the body. The mechanical properties of prostate cancer cells treated with the most commonly used anti-cancer drugs have been investigated at the Institute of Nuclear Physics of the Polish Academy of Sciences in Cracow.
Scientists from the UK's University of Bath explore racemases - an important type of enzyme that is linked to certain cancers and other life-threatening diseases while also being critical to cell function - in a paper published in the prestigious journal Chemical Society Reviews. The scientists also propose new strategies for finding drugs that neutralize these enzymes.